Peter A. Kaufman - Concepedia

Author

Peter A. Kaufman

Dartmouth–Hitchcock Medical Center ORCID

Also Known As

Kaufman, Peter A., P A Kaufman, P KAUFMAN, P Kaufman, P. A. Kaufman, P. KAUFMAN, P. Kaufman, P.A. Kaufman, P. A. Kaufman, PAUL KAUFMAN

339

Publications

21.1K

Citations

H-Index

211

Concepts

All Affiliations

Dartmouth–Hitchcock Medical Center Dartmouth College Mayo Clinic in Florida Sarah Cannon Dana-Farber Cancer Institute

About

Peter A. Kaufman is an author at Dartmouth–Hitchcock Medical Center specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	15	20	1.7K
2	Engineering	6	6	687
3	Business	5	5	1.4K
4	Education	3	3	87
5	Arts	1	1	12

Peter A. Kaufman

126

Publications

20.5K

Citations

H-Index

Page 1

	Year	Citations
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer Edward H. Romond, Edith A. Perez, John Bryant, New England Journal of Medicine	2005	5.3K
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy George W. Sledge, Masakazu Toi, Patrick Neven, Journal of Clinical Oncology Breast OncologyCancer ManagementGynecologyPharmacotherapyPurpose Monarch 2	2017	1.6K
The Role of Relational Information Processes and Technology Use in Customer Relationship Management Satish Jayachandran, Subhash Sharma, Peter A. Kaufman, Journal of Marketing Customer SatisfactionBusiness IntelligenceDigital MarketingBusiness AnalyticsTechnology Use	2005	962
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 George W. Sledge, Masakazu Toi, Patrick Neven, JAMA Oncology	2019	941
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Sandra M. Swain, David Miles, Sung‐Bae Kim, The Lancet Oncology End-of-study ResultsBreast OncologyMedicineClinical TrialsPathology	2020	854
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31 Edith A. Perez, Edward H. Romond, Vera J. Suman, Journal of Clinical Oncology	2011	712
Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial Edith A. Perez, Vera J. Suman, Nancy E. Davidson, Journal of Clinical Oncology	2008	541
Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive Reserve Tim A. Ahles, Andrew J. Saykin, Brenna C. McDonald, Journal of Clinical Oncology	2010	525
<i>HER2</i> Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial Edith A. Perez, Vera J. Suman, Nancy E. Davidson, Journal of Clinical Oncology	2006	443
Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane Peter A. Kaufman, Ahmad Awada, Chris Twelves, Journal of Clinical Oncology	2015	442

Page 1